Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme

Neuro-Oncology

Volumn 13, Issue 5, 2011, Pages 546-557

  Li, Yan ^a,c   Lupo, Janine M ^a   Polley, Mei Yin ^a   Crane, Jason C ^a   Bian, Wei ^a   Cha, Soonmee ^a   Chang, Susan ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSF Radiology   (United States)

Author keywords

Glioblastoma multiforme; Magnetic resonance imaging; Survival

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CORTICOSTEROID; ERLOTINIB; GADOLINIUM PENTETATE; TEMOZOLOMIDE; TIPIFARNIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; BRAIN BLOOD VOLUME; BRAIN PERFUSION; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SURVIVAL TIME;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TIME FACTORS; TUMOR BURDEN;

EID: 79959955739     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq194     Document Type: Conference Paper

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
3. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009;6:648-657.
4. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59:1617-1625. (Pubitemid 17060106)
5. Hohwieler Schloss M, Freidberg SR, Heatley GJ, Lo TC. Glucocorticoid dependency as a prognostic factor in radiotherapy for cerebral gliomas. Acta Oncol. 1989;28:51-55. (Pubitemid 19113621)
6. Etienne MC, Formento JL, Lebrun-Frenay C, et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res. 1998;4:2383-2390. (Pubitemid 28477903)
7. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198. (Pubitemid 32799739)
8. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
9. Stark AM, Hedderich J, Held-Feindt J, Mehdorn HM. Glioblastoma-the consequences of advanced patient age on treatment, survival. Neurosurg Rev. 2007;30:56-61; discussion 61-62. (Pubitemid 44900242)
10. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62:564-576; discussion 564-576.
11. Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008;10:79-87. (Pubitemid 351250903)
12. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65-73. (Pubitemid 26052641)
13. Saraswathy S, Crawford FW, Lamborn KR, et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. J Neurooncol. 2009;91:69-81.
14. Crawford FW, Khayal IS, McGue C, et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol. 2009;91:337-351.
15. Nelson SJ, Nalbandian AB, Proctor E, Vigneron DB. Registration of images from sequential MR studies of the brain. J Magn Reson Imaging. 1994;4:877-883.
16. Hartkens T D R, Schnabel JA, Hawkes DJ, Hill D L G. VTK CISG Registration Toolkit: An open source software package for affine and non-rigid registration of single-and multimodal 3D images. In: BVM; 2002; Leipzig, Germany: Springer-Verlag, 2002: Abstract 185.
17. Lee MC, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. J Magn Reson Imaging. 2005;21:683-693. (Pubitemid 40770859)
18. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibilityweighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol. 2005;26:1446-1454. (Pubitemid 43733445)
19. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model and the expectationmaximization algorithm. IEEE Trans Med Imaging. 2001;20:45-57. (Pubitemid 32293419)
20. Saraswathy S, Crawford F, Nelson SJ. Semi-automated segmentation of brain tumor lesions in MR images. In: 14th Annual Meeting of ISMRM; 2006; Abstract 1609.
21. Aydemir U, Aydemir S, Dirschedl P. Analysis of time-dependent covariates in failure time data. Stat Med. 1999;18:2123-2134. (Pubitemid 29408255)
22. Kreth FW, Berlis A, Spiropoulou V, et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer. 1999;86:2117-2123.
23. Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008;69:506-509; discussion 509.
24. Soults CB, Canute GS, Ryken TC. Evidence-based review of the role of reoperation in the management of malignant glioma. Neurosurg Focus. 1998;4:e11.
25. Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008;22:452-455. (Pubitemid 351878614)
26. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005;103:428-438. (Pubitemid 43186633)
27. Pirzkall A, McGue C, Saraswathy S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2009;11:842-852.
28. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453-461. (Pubitemid 351597795)
29. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009;72:423-428.
30. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol. 2000;21:881-890. (Pubitemid 30262835)
31. Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol. 2009;30:681-688.
32. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol. 1997;32:253-265. (Pubitemid 27077976)
33. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 1997;57:3860-3864. (Pubitemid 27381236)
34. Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A. Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review. Eur Rev Med Pharmacol Sci. 1997;1:17-25. (Pubitemid 28078765)
35. Brat DJ, Van Meir EG. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol. 2001;158:789-796. (Pubitemid 32221771)
36. Trnovec T, Kallay Z, Bezek S. Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances. Int J Radiat Oncol Biol Phys. 1990;19:1581-1587.
37. Rubin P, Gash DM, Hansen JT, Nelson DF, Williams JP. Disruption of the blood-brain barrier as the primary effect of CNS irradiation. Radiother Oncol. 1994;31:51-60. (Pubitemid 24167590)
38. Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22:1081-1088. (Pubitemid 32587420)
39. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177-183. (Pubitemid 34680392)
40. Muti M, Aprile I, Principi M, et al. Study on the variations of the apparent diffusion coefficient in areas of solid tumor in high grade gliomas. Magn Reson Imaging. 2002;20:635-641. (Pubitemid 35477492)
41. Plowman PN. Stereotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg. 1999;13:256-264. (Pubitemid 29304495)
42. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE. Tumor angiogenesis-a new therapeutic target in gliomas. Acta Neurol Scand. 1998;97:52-62. (Pubitemid 28057388)
43. Franceschi E, Tosoni A, Bartolini S, Mazzocchi V, Fioravanti A, Brandes AA. Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther. 2009;9:613-619.
44. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Bio Drugs. 2009;23:289-304.
45. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27:2905-2908.